Figures & data
Table 1. Patient characteristics treated by nivolumab (n = 58).
Figure 1. Time to treatment failure (a) and overall survival (b) for patients (n = 58) treated with nivolumab in named patient program.
![Figure 1. Time to treatment failure (a) and overall survival (b) for patients (n = 58) treated with nivolumab in named patient program.](/cms/asset/48b90e12-d08c-4c98-9529-1b8b0371b98c/ionc_a_1253865_f0001_b.jpg)
Figure 2. Overall survival for patients with non-squamous carcinoma (n = 34, solid line) or squamous cell carcinoma (n = 24, dotted line).
![Figure 2. Overall survival for patients with non-squamous carcinoma (n = 34, solid line) or squamous cell carcinoma (n = 24, dotted line).](/cms/asset/bd093fe6-b062-4f24-adf4-07e53e72034d/ionc_a_1253865_f0002_b.jpg)
Figure 3. Time (months) from diagnosis to nivolumab treatment start (white), time on nivolumab treatment (black) and post-nivolumab survival time (grey). Each bar represents one patient. Patients still alive are marked with arrow.
![Figure 3. Time (months) from diagnosis to nivolumab treatment start (white), time on nivolumab treatment (black) and post-nivolumab survival time (grey). Each bar represents one patient. Patients still alive are marked with arrow.](/cms/asset/222c211a-44cc-4b3e-b364-0621ee30be99/ionc_a_1253865_f0003_b.jpg)
Table 2. Adverse events during nivolumab therapy (n = 58).